Predictive factors for survival and correlation to toxicity in advanced Stage III non-small cell lung cancer patients with concurrent chemoradiation

Japanese Journal of Clinical Oncology

Volumn 46, Issue 2, 2016, Pages 144-151

  Kim, Yong Hyub ^a   Ahn, Sung Ja ^a,b   Kim, Young Chul ^b   Kim, Kyu Sik ^b   Oh, In Jae ^b   Ban, Hee Jung ^b   Chung, Woong Ki ^a   Nam, Taek Keun ^a,b   Yoon, Mee Sun ^a,b   Jeong, Jae Uk ^a,b   Song, Ju Young ^a  

^a Chonnam National University Medical School   (South Korea)

^b Jeonnam Regional Cancer Center   (South Korea)

Author keywords

Concurrent chemoradiotherapy; Locally advanced non small cell lung cancer; Prognostic subgroups; Toxicity

Indexed keywords

ADULT; AGE; AGED; ARTICLE; BLOOD GAS PARAMETERS; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; DIFFUSION LUNG CAPACITY FOR CARBON MONOXIDE; ESOPHAGEAL TOXICITY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LUNG CAPACITY; LUNG TOXICITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CODING; PHYSICAL PERFORMANCE; RADIATION HAZARD; RETROSPECTIVE STUDY; SURVIVAL TIME; TUMOR VOLUME; VERY ELDERLY; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CONFORMAL RADIOTHERAPY; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RADIATION INJURIES; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DEOXYCYTIDINE; DOCETAXEL; GEMCITABINE; PACLITAXEL; TAXOID;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CISPLATIN; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PROPORTIONAL HAZARDS MODELS; RADIATION INJURIES; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 84961613482     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyv174     Document Type: Article

References (26)

1. Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010;28:2181-90.
2. Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 2005;23:5910-7.
3. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999;17:2692-9.
4. Gewanter RM, Rosenzweig KE, Chang JY, et al. ACR Appropriateness Criteria: nonsurgical treatment for non-small-cell lung cancer: good performance status/definitive intent. Curr Probl Cancer 2010;34:228-49.
5. Ademuyiwa FO, Johnson CS, White AS, et al. Prognostic factors in stage III non-small-cell lung cancer. Clin Lung Cancer 2007;8:478-82.
6. Rusch VW, Asamura H, Watanabe H, et al. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2009;4:568-77.
7. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31:1341-6.
8. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002;122:1037-57.
9. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline:update 2003. J Clin Oncol 2004;22:330-53.
10. Dehing-Oberije C, Yu S, De Ruysscher D, et al. Development and external validation of prognostic model for 2-year survival of non-small-cell lung cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009;74:355-62.
11. Socinski MA, Zhang C, Herndon JE 2nd, et al. Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. Ann Oncol 2004;15:1033-41.
12. Stinchcombe TE, Hodgson L, Herndon JE 2nd, et al. Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. J Thorac Oncol 2009;4:1117-25.
13. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
14. Asmis TR, Ding K, Seymour L, et al. Age and comorbidity as independent prognostic factors in the treatment of nonsmall-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol 2008;26:54-9.
15. Janssen-Heijnen ML, Smulders S, Lemmens VE, et al. Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax 2004;59:602-7.
16. Gridelli C, Langer C, Maione P, et al. Lung cancer in the elderly. J Clin Oncol 2007;25:1898-07.
17. Takigawa N, Kiura K, Segawa Y, et al. Benefits and adverse events among elderly patients receiving concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: analysis of the Okayama Lung Cancer Study Group trial 0007. J Thorac Oncol 2011;6:1087-91.
18. Lopez Guerra JL, Gomez D, Zhuang Y, et al. Change in diffusing capacity after radiation as an objective measure for grading radiation pneumonitis in patients treated for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2012;83:1573-9.
19. Lopez Guerra JL, Gomez DR, Zhuang Y, et al. Changes in pulmonary function after three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, or proton beam therapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2012;83:e537-43.
20. Videtic GM, Stitt LW, Ash RB, et al. Impaired diffusion capacity predicts for decreased treatment tolerance and survival in limited stage small cell lung cancer patients treated with concurrent chemoradiation. Lung Cancer 2004;43:159-66.
21. Chapman JD, Bradley JD, Eary JF, et al. Molecular (functional) imaging for radiotherapy applications: an RTOG symposium. Int J Radiat Oncol Biol Phys 2003;55:294-301.
22. Alexander BM, Othus M, Caglar HB, Allen AM. Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys 2011;79:1381-7.
23. Dehing-Oberije C, De Ruysscher D, van derWeide H, et al. Tumor volume combined with number of positive lymph node stations is a more important prognostic factor thanTNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy. Int J Radiat Oncol Biol Phys 2008;70:1039-44.
24. Fernandes AT, Mitra N, Xanthopoulos E, et al. The impact of extent and location of mediastinal lymph node involvement on survival in Stage III non-small cell lung cancer patients treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys 2012;83:340-7.
25. Cox JD, Pajak TF, Asbell S, et al. Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys 1993;27:493-8.
26. Machtay M, Hsu C, Komaki R, et al. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. Int J Radiat Oncol Biol Phys 2005;63:667-71.